Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX

BACKGROUND: Korean National Health Insurance reimburses factor VIII (FVIII) and factor IX (FIX) clotting factor concentrate (CFC) infusions to discrepant activity levels, allowing elevation of FVIII activity to 60 IU/dL and FIX to 40 IU/dL. We aimed to assess hemostatic response to these target leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Ki-Young, Jung, Soo-Young, Hwang, Sung-Ho, Lee, Su-Min, Park, Jong-Ho, Nam, Hyun-Ja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898993/
https://www.ncbi.nlm.nih.gov/pubmed/29662861
http://dx.doi.org/10.5045/br.2018.53.1.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898993/
https://www.ncbi.nlm.nih.gov/pubmed/29662861
http://dx.doi.org/10.5045/br.2018.53.1.41

Ejemplares similares